Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Swedish Medical Center5 enrolled

Overview

Open label study of sorafenib

Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers (less than \< 100 cigarettes lifetime).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lung Cancer

Interventions

sorafenibDRUG

400mg po bid

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 * Life expectancy \> 12 weeks * Biopsy-proven BAC or adenocarcinoma * Willing to provide smoking status * Selected IIIB or stage IV cancer that is incompletely resected or unresectable Exclusion Criteria: * O2 saturation \< 88% on room air * Pregnant or nursing women * Surgery or radiation therapy within 4 weeks of starting study * Major heart condition within 6 months of starting therapy * Certain concomitant medications prohibited

Locations (1)

Swedish Cancer Institute

Seattle, Washington, United States

Outcomes

Primary Outcomes

Response rate

Time frame: January 2009

One-year survival

Time frame: January 2009

Median survival

Time frame: January 2009

Secondary Outcomes

Median progression-free survival

Time frame: January 2009

Toxicities

Time frame: January 2009

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.